Nasdaq
$6.51▼ 2.69%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $135.7MShares out 20.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 4d agoPre-market26.10.21 20:006-KKey event#●●●#●●●
Satellos Bioscience Inc.
Satellos Bioscience announced that its management will participate in the Guggenheim and Jefferies healthcare investor conferences in November 2026. The company plans to discuss the clinical progress of its muscle disease treatment candidate, forazapadin, and its future development strategy with investors.…more
$6.51-2.69%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5Pre-market26.10.05 20:006-KKey event
Satellos Bioscience Inc.
Satellos Bioscience has been granted a U.S. composition of matter patent for its lead clinical-stage drug candidate, forazapadin. This patent provides intellectual property protection through September 6, 2044, strengthening the company's long-term development and commercialization strategy.…more
$6.51-2.69%vs prev closeView filingShare - 9.30Pre-market26.09.30 20:006-KKey event
Satellos Bioscience Inc.
Satellos Bioscience has completed enrollment for the Phase 2 BASECAMP clinical trial of its drug candidate forazapadin for the treatment of Duchenne muscular dystrophy (DMD). The company is adjusting its data release schedule to ensure a comprehensive dataset and now intends to report topline clinical results in the first quarter of 2027.…more
$6.51-2.69%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 20:00#●●●#●●●
Satellos Bioscience to Participate in Upcoming Investor Conferences
Satellos Bioscience announced that its management team will participate in upcoming healthcare investor conferences in November. The company will engage in fireside chats and one-on-one meetings with investors to discuss its clinical-stage developments.…more
$6.51-2.69%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.5Pre-market26.10.05 20:00
●●●●●●●● ●●●●● ●●●●●●
Satellos Bioscience has secured a U.S. composition of matter patent for its lead clinical-stage drug candidate, forazapadin, providing intellectual property protection until 2044. While this strengthens the company's IP portfolio, the long-term impact on stock value remains dependent on the success of ongoing clinical trials.…more
$6.51-2.69%vs prev close - 9.30Pre-market26.09.30 20:00
●●●●●●●● ●●●●● ●●●●●●
Satellos has successfully completed patient enrollment for its Phase 2 clinical trial of forazapadin for Duchenne muscular dystrophy. The company has adjusted its data release timeline to the first quarter of 2027 to ensure a comprehensive analysis of the trial results.…more
$6.51-2.69%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report